Home > Cardiology > ACC 2021 > Valvular Heart Disease > Preliminary results encouraging for EVOQUE tricuspid valve replacement

Preliminary results encouraging for EVOQUE tricuspid valve replacement

Presented By
Dr Susheel Kodali , Columbia University Medical Center, USA
Conference
ACC 2021
Trial
TRISCEND
In patients with significant tricuspid regurgitation (TR) who received a new tricuspid valve replacement system, results at 30 days showed a reduction of TR and improvement of symptoms in the TRISCEND study. At 30 days, most patients (77.4%) had experienced no major adverse events. The device was deemed technically feasible, with an acceptable safety profile [1]. The TRISCEND study (NCT04221490) was an early feasibility study to assess the performance and safety of the Edwards’ EVOQUE tricuspid valve replacement system. This prospective, single-arm, multicentre study enrolled 56 patients with symptomatic moderate or greater TR to receive the EVOQUE valve replacement. At 30 days, 47 participants were available for follow-up. The participants were quite elderly (mean age 79 years) and had severe TR symptomatic (92% graded as severe or greater). A...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on